4.49
-5.27%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tonix Pharmaceuticals Holding
From its filings with the US Securities and Exchange Commission
Tonix Pharmaceuticals Holding is based in Berkeley Heights, New Jersey and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker TNXP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $13.1m and a net loss of $124.0m. At that date it held total assets of $277.2m and shareholders' equity of $245.2m. By business, Zembrace Symtouch [Member] brought in 71.1% of revenue, followed by Tosymra [Member] at 18.1% and Tonmya [Member] at 10.8%.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Mar 2010
- Employees
- 142
- Website
- tonixpharma.com ↗
- Head office
- 200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NJ, 07922
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Seth LedermanChairman of the Board, President, Chief Executive Officer, since 2011$1.8m
- Mr. Bradley SaengerChief Financial Officer, Treasurer$849,981
- Ms. Jessica MorrisChief Operating Officer$887,741
- Ms. Siobhan FogartyChief Technical Officer
- Dr. Gregory SullivanChief Medical Officer, Secretary$922,444
- Mr. James TrecoLead Independent Director$91,499
- Mr. James HunterDirector
- Mr. Richard BaggerIndependent Director$71,499
- Ms. Margaret BellIndependent Director$71,499
- Maj. Gen. (Retd.) David GrangeIndependent Director$71,499
- Dr. Adeoye OlukotunIndependent Director$71,499
- Mr. R. Newcomb StillwellIndependent Director$71,499
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 39
- Social
- 18
- Governance
- 45
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tonix Pharmaceuticals has completed Phase IIb BESTFIT trial for TNX-102 SL in fibromyalgia.
- The company is conducting Phase III AFFIRM study for fibromyalgia treatment with TNX-102 SL.
- Tonix's TNX-102 SL is in Phase II clinical trial for military-related PTSD under AtEase trial.
Weaknesses
- Tonix employs only 142 full-time employees in the US biotechnology sector.
- The company's clinical-stage development focuses on CNS disorders with limited product diversity.
- Tonix has only one product candidate in clinical development for registration in two indications.
Opportunities
- Tonix's TNX-102 SL shows potential for registration in fibromyalgia and PTSD indications.
- The company's pipeline includes TNX-301 as a fixed dose combination drug product for future development.
- Phase III AFFIRM study completion could lead to market entry for fibromyalgia treatment.
Threats
- Tonix faces competition in the US biotechnology sector for CNS disorder treatments.
- The clinical development of TNX-102 SL for PTSD may face regulatory challenges in military-related trials.
- Limited employee count of 142 may hinder rapid expansion in the biopharmaceutical industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.